Boardroom Alpha
Meeting calendar
NKLR · Annual meeting · Monday, November 16, 2026

Terra Innovatum Global NV

8 nominees · 6 ballot items.

Shareholders will vote on financial year 2025 matters, the reappointment or appointment of eight directors, equity-based director remuneration limits and criteria, amendments to the remuneration policy, authorization for the Board to repurchase shares, and withdrawal of KPMG’s Dutch statutory audit engagement.

Market cap
$254M
1Y TSR
-54.3%
Board grade
C-
Record date
Oct 19, 2026
Filing
DEF 14A
Filed Oct 27, 2026 · DEF 14A
Proposals

On the ballot6

  1. 1

    Financial Year 2025 Matters

    ManagementBoard: FOR

    This agenda item includes discussion of the 2025 annual accounts, ratification of a five-month extension for their preparation, discharge of directors from liability for disclosed duties during 2025, and adoption of the 2025 Dutch statutory annual accounts. Only items 1(b), 1(c), and 1(d) are voting items; item 1(a) is discussion-only.

    More detail

    Proposal 1 addresses several statutory matters concerning the Company’s 2025 financial year. Shareholders will discuss the 2025 annual accounts, but no vote is required on that discussion item. They will vote on ratifying an additional five-month preparation period under Section 2:101 of the Dutch Civil Code because the Board could not complete the accounts within the initial five-month statutory period due to special circumstances. The Board states that the annual accounts have since been completed, reducing the proposal’s practical effect to formal ratification of the earlier extension. Shareholders will also vote on discharging directors from liability for duties performed during 2025 to the extent those duties were disclosed in the annual accounts or otherwise publicly disclosed before adoption. Finally, shareholders are asked to adopt the Dutch statutory annual accounts, which are prepared under Dutch GAAP and differ from the U.S. GAAP consolidated financial statements in the Form 10-K. The discharge proposal is non-routine, while the extension and adoption proposals are treated as routine matters for broker voting purposes. The Board unanimously recommends voting FOR each voting item, and the filing does not identify opposition or a competing shareholder position.

  2. 2

    Reappointment and Appointment of Directors of the Company

    ManagementBoard: FOR

    Shareholders are asked, under the Board’s binding nomination, to reappoint Alessandro Petruzzi and Massimo Morichi and appoint Katherine Crocker Williams, Joanna Lyn Lohkamp, Kostadin N. Ivanov, Mamdouh El-Shanawany, S. Michael Modro, and Tony Tullio for terms ending at the 2027 annual general meeting.

  3. 3

    Approval of the Maximum Number of Shares and Criteria Applicable to Equity-Based Remuneration for Directors of the Board

    ManagementBoard: FOR

    Shareholders are asked to approve an aggregate pool of up to 2,000,000 ordinary shares or rights to acquire ordinary shares for director remuneration from November 16, 2026 through December 31, 2029, with annual increases of up to 250,000 shares and specified performance criteria.

    More detail

    Proposal 3 seeks shareholder approval for a substantial equity pool that can be used to compensate Board members over the period from November 16, 2026 through December 31, 2029. The requested authorization covers up to 2,000,000 ordinary shares or rights to acquire shares without additional shareholder approval. The pool may increase by as much as 250,000 shares per year, including through applicable evergreen provisions. Awards may be based on financial, operational, strategic, organizational, individual-performance, and new-hire criteria. Individual performance may support no more than 50% of the aggregate pool, providing a stated limitation on purely discretionary allocation. Management explains that awards are expected to be made under the existing Equity Incentive Plan and that the proposal does not itself increase the plan’s overall share reserve. The proposal is required because Article 21.4 of the Company’s articles requires shareholder approval specifying the maximum number and criteria for equity-based director remuneration. The Board recommends FOR, while acknowledging that directors and nominees have an interest because they may be eligible for awards and that actual benefits are not currently determinable.

  4. 4

    Approval of the Amendment of the Remuneration Policy of the Company

    ManagementBoard: FOR

    Shareholders are asked to approve amendments permitting additional committee fees for non-executive directors, establishing executive-director short-term incentive opportunities, and allowing a future long-term incentive plan for executive directors.

    More detail

    Proposal 4 asks shareholders to approve a binding amendment to the Company’s remuneration policy under Section 2:135a(2) of the Dutch Civil Code. The amendment would authorize additional cash compensation for non-executive directors who serve on ad hoc, special, or other Board committees. It would establish a target annual short-term incentive for executive directors equal to 100% of base salary. The maximum would be 100% of base salary when paid entirely in cash, or up to 250% of base salary to the extent settled in equity under the Equity Incentive Plan. The actual award could range from zero to the applicable maximum and would be determined by non-executive directors based on performance. The amendment would also permit a future long-term incentive plan involving shares, options, cash-settled awards, or combinations of those instruments. Any equity awards remain subject to the Equity Incentive Plan, required shareholder approvals, and applicable law. The Board supports the proposal, while the filing notes that all directors and nominees have an interest because they may receive remuneration under the amended policy.

  5. 5

    Authorization of the Board to Acquire Shares in Its Own Capital

    ManagementBoard: FOR

    Shareholders are asked to authorize the Board for 18 months to repurchase up to 10% of issued share capital through specified market or private transactions at a price above zero and no more than 110% of the applicable five-day average Nasdaq market price.

    More detail

    Proposal 5 requests a broad authorization for the Board to repurchase the Company’s fully paid shares for 18 months after the AGM. Purchases could occur through derivatives, open-market transactions, private purchases, block trades, or other methods. The authorization would be capped at 10% of issued share capital as measured on the AGM date. The purchase price must be greater than zero and no more than 110% of the average Nasdaq closing price over the five trading days preceding agreement on the acquisition. The authority would provide flexibility to manage the Company’s capital structure and potentially respond to market conditions. The Company expressly states that it does not currently intend to exercise the authorization, so the immediate capital-allocation impact is prospective rather than planned. The proposal is classified as routine, allowing brokers or nominees discretion to vote uninstructed shares. The Board recommends FOR, and the filing provides no additional company-specific repurchase rationale beyond the requested flexibility.

  6. 6

    Withdrawal of the Dutch Audit Engagement of KPMG Accountants N.V. as External Dutch Auditor for the Financial Year Ending 2025

    ManagementBoard: FOR

    Shareholders are asked to withdraw KPMG’s Dutch statutory audit engagement for 2025 because the Company qualifies as a small legal entity exempt from the statutory audit requirement; the withdrawal is separate from KPMG’s U.S. registered-public-accounting-firm dismissal.

Director elections

Nominees on the ballot8

Katherine Crocker Williams
Not independent
Tenure on this board
New nominee
Joanna Lyn Lohkamp
Independent
Tenure on this board
New nominee
Kostadin N. Ivanov
Independent
Tenure on this board
New nominee
Mamdouh El-Shanawany
Independent
Tenure on this board
New nominee
S. Michael Modro
Independent
Tenure on this board
New nominee
Tony Tullio
Independent
Tenure on this board
New nominee
Ownership

Top institutional holders10

Latest 13F quarter
1EXCHANGE TRADED CONCEPTS, LLC3.0%3,350,629$16M
2SEGRA CAPITAL MANAGEMENT, LLC2.4%2,617,152$13M
3Magnetar Financial LLC0.7%765,603$4M
4HATCH COVE CAPITAL, LLC0.2%270,300$1M
5Cerity Partners LLC0.2%261,207$1M
6Cable Car Capital, LP0.2%215,000$1M
7AQR Arbitrage LLC0.2%185,903$915K
8Hudson Bay Capital Management LP0.2%185,900$792K
9LINDEN ADVISORS LP0.2%171,535$799K
10UBS Group AG0.2%171,420$843K
Filings

Terra Innovatum Global NV proxy statements and SEC reports

Annual & quarterly reports (10-K, 10-Q)
Proxy statements (DEF 14A)
Reference

Frequently asked questions

When is the Terra Innovatum Global NV 2026 annual meeting?
Terra Innovatum Global NV (NKLR) holds its 2026 annual shareholder meeting on Monday, November 16, 2026.
What is the record date for the Terra Innovatum Global NV 2026 meeting?
The record date for the Terra Innovatum Global NV 2026 meeting is Monday, October 19, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Terra Innovatum Global NV's 2026 meeting?
The board is presenting 8 director nominees at the Terra Innovatum Global NV 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Terra Innovatum Global NV 2026 meeting?
Shareholders will vote on 6 proposals at the Terra Innovatum Global NV 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer